Rare diseases reveal that our sense of identity rests on fragile biological infrastructure, much of it operating outside ...

Data highlights symptom stability and enhanced efficacy signals in higher dose group –– Analysis offers valuable insights to guide ongoing ...

Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.

Alterity Therapeutics’ phase II study of its lead compound ATH434 in multiple system atrophy (MSA) has been featured in an ...

Parkinson’s Disease Causes, Symptoms, and Treatment Parkinson’s disease (PD) is one of the fastest-growing neurological ...

Chennai: A new AI-enabled deep brain stimulation (DBS) device, one that can read brain signals and adjust itself, will be ...

Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here.

As Part of an Exploratory Outcome, ABLi Therapeutics Used CND's Syn-One Biomarker Services to Quantify and Visualize a Decrease in Phosphorylated Alpha-Synuclein in Cutaneous Nerves of Patients in a ...

As of November 12, 2025, ProMIS has fully enrolled Cohorts 1 and 2 and is well into Cohort 3, with complete enrollment expected before the end of the year. PMN310 continues to demonstrate a favorable ...

In an exclusive interview, Alterity Therapeutics’ ( ATHE) CEO David Stamler met with The Fly to discuss the company, the biotech industry, ongoing trials, upcoming milestones and much more.

Shares in Theravance Biopharma ( TBPH +24.80%) surged by more than 21% as of noontime ET today. The move comes as the market ...